论文信息 - Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer - 字舞流文

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

E. Winer | K. Polyak | R. Gelman | A. Bardia | N. Lin | J. Brock | J. Balko | B. Overmoyer | F. Michor | Yaomin Xu | Yu Wang | V. Wang | S. Tolaney | D. Stover | Hao Guo | M. Lloyd | Carlos R Gil Del Alcazar | Qiong Xu